PharmaCyte Biotech, Inc. provided earnings guidance for Fiscal Year 2022. Net loss for fiscal year 2022 is expected to be approximately $4.2 million or approximately $0.27 per share, compared with a net loss of $3.6 million, or $2.45 per share, for the prior fiscal year.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.01 USD | +1.15% | -0.50% | -6.94% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-6.94% | 16.8M | |
+43.34% | 749B | |
+39.42% | 605B | |
-6.67% | 351B | |
+19.02% | 328B | |
+8.36% | 292B | |
+11.92% | 216B | |
-2.62% | 214B | |
+0.25% | 167B | |
+5.95% | 165B |
- Stock Market
- Equities
- PMCB Stock
- News PharmaCyte Biotech, Inc.
- PharmaCyte Biotech, Inc. Provides Earnings Guidance for Fiscal Year 2022